Testimonials and results contained within may not be an implication of future results and are based on the experiences of a few people and you may not have similar results
AOD9604 has been characterised across pre-clinical, safety pharmacology, and early-phase clinical research since the late 1990s, with peer-reviewed publications spanning lipid metabolism, adipose biology, joint repair, and bioavailability
It was marketed under the brand name Byetta and got approval in 2005
Systemic treatment can be recommended in widespread disease (affecting multiple body areas) or in patients with a single area with large involvement and significant inflammation
We have overseas warehouses in Germany, USA, Nuevo Laredo, Mexico, Vancouver, Toronto, Canada, Amsterdam, Netherlands and Sydney, Melbourne, Australia